The intersection of AI and immunology is revolutionizing how we understand and treat complex immune disorders. In this episode of the AWS Health Innovation Podcast, Mike Tarselli, Specialist Leader for HCLS Data & AI, explores the future of precision immunology with Gregory Vladimer, Scientific Co-Founder & CEO of Graph Therapeutics. Graph's innovative approach combines AI-powered analysis with patient cell behavior to develop targeted therapies for millions affected by immune-mediated diseases.

1. How does one transition from immunology research to leading a TechBio company?
   • Gregory Vladimer's evolution from bench scientist to CEO reflects the changing landscape of drug discovery leadership, where deep scientific expertise meets technological innovation.
2. What distinguishes TechBio 3.0 from earlier approaches?
   • Modern TechBio companies like Graph represent a more sophisticated model, combining specialized domain knowledge with strategic tech partnerships to enhance drug discovery capabilities.
3. How does Graph's approach to precision medicine differ?
   • By leveraging functional perturbation modeling and multi-omics data analysis, Graph applies precision oncology principles to decode and treat complex immune conditions like rheumatoid arthritis and Crohn's disease.
4. What role does AI play in Graph's drug discovery platform?
   • Advanced machine learning systems analyze complex biological data across multiple endpoints, while maintaining scientific rigor through human-in-the-loop validation processes.
5. What's the long-term vision for immune disease treatment?
   • Graph focuses on building predictive disease models and a comprehensive target generation engine, prioritizing curative potential over rapid commercialization.

Learn more about Graph Therapeutics at https://graphtx.com/

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Heart failure affects over 60 million people worldwide, yet monitoring blood pressure inside the heart remains an invasive, complex procedure. In this episode of the AWS Health Innovation Podcast, Guy Spigelman, EMEA lead for Healthcare and Life Sciences Startups at AWS, speaks with Filip Peters, CEO of Acorai, about their groundbreaking non-invasive SAVE Sensor System that combines multiple sensing technologies to measure intracardiac pressures - potentially transforming how we manage heart failure.

• Drawing from his background in machine learning and financial technology, Filip identified an opportunity to apply advanced analytics to cardiac monitoring. His transition exemplifies how cross-industry expertise can drive healthcare innovation.

• The system integrates four distinct sensor types - seismic, acoustic, visual, and electrical - creating a comprehensive approach to non-invasive cardiac monitoring. This novel combination enables detailed measurement of intracardiac pressures without invasive procedures.

• By enabling frequent, non-invasive pressure monitoring, healthcare providers can track heart failure progression more effectively. This capability supports earlier interventions and more precise treatment adjustments, potentially improving outcomes for millions of patients.

• Acorai prioritized portability and user experience, creating an intuitive interface that integrates seamlessly with existing hospital workflows. This practical approach addresses key adoption barriers in clinical settings.

• The company has expanded operations across six countries and received FDA Breakthrough Device Designation, demonstrating strong market validation and regulatory progress. These achievements reflect growing confidence in Acorai's innovative approach.

Learn more about Acorai at https://acorai.com/

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

The complex relationship between bacteria and medication efficacy represents one of medicine's most overlooked frontiers. In this episode of the AWS Health Innovation Podcast, Amrita Sarkar, GenAI Leader for Health & Bio at AWS Startups, speaks with Nik Sharma (CEO and Co-Founder) and Muhannad Alomari (CTO and Co-Founder) of BioCorteX. Their groundbreaking work in computational drug-bacteria interaction analysis is reshaping our understanding of personalized medicine and drug development.

1. What inspired BioCorteX's approach to pharmaceutical development?
   • People living with diseases cannot wait. Drawing from tried and tested engineering methodology, BioCorteX applies sophisticated engineering principles to transform drug development success rates by exploring the drug-bacteria interactions. This cross-industry innovation demonstrates how established engineering practices can revolutionize pharmaceutical outcomes.
2. What role does evolutionary biology play in BioCorteX's research methodology?
   • The company's approach is fundamentally built on the fact that mitochondria – the power house of cells – are ex-bacteria. This deep historical connection provides crucial insights into how bacterial interactions influence medication responses across diverse populations.
3. How does BioCorteX manage the complexity of human-bacterial interactions?
   • Understanding biology is one of the most complex tasks that humanity has ever attempted to tackle , with human bacteria interactions that far exceeds the number of stars in our galaxy. Their proprietary Carbon Mirror technology employs advanced emulation technologies to analyze drug-bacteria relationships at an unprecedented scale. This in-silico approach enables the exploration of complex interactions that traditional laboratory methods simply cannot possibly capture.
4. What makes BioCorteX's data approach unique in pharmaceutical development?
   • The Carbon Knowledge platform leverages 15 million samples from 165 different geopolitical regions worldwide, enabling highly accurate drug trial outcome predictions. The scale and geographical breadth of this highly curated data help optimize clinical trials and enhance success rates for pharmaceutical companies.
5. How does BioCorteX maintain efficiency with a lean team structure?
   • Operating with just twelve team members, BioCorteX maintains an strong and radically transparent culture where everyone codes while partnering with major industry players. Their focus on scalable output and revenue generation challenges traditional startup growth models.
6. What does BioCorteX's future in personalized medicine look like?
   • The recent partnership with Tempus demonstrates BioCorteX's commitment to advancing personalized medicine. Their technology platform is positioned to fundamentally change how pharmaceutical companies approach drug development and patient care particularly when moving assets across regions i.e China to Global.

Learn more about BioCorteX at https://BioCorteX.com/

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

What if you could peer into the future of a clinical trial before enrolling a single patient? In this episode of the AWS Health Innovation Podcast, Alex Merwin, Head of Growth for Healthcare & Life Science Startups at AWS, sits down with Orr Inbar, Co-Founder & CEO of QuantHealth, to explore their groundbreaking platform that's revolutionizing drug development through clinical trial simulation. Their technology is transforming how pharmaceutical companies evaluate and advance potential therapies.

• By leveraging an extensive database of 350 million patient records and sophisticated AI models, QuantHealth's platform achieves an impressive 86% accuracy in predicting trial outcomes. This capability directly addresses the industry's persistent challenges of rising costs and high failure rates.

• The pharmaceutical industry struggles with average development costs of $3 billion and timelines exceeding a decade. Modern precision medicine requirements have added new layers of complexity to the drug development process, making traditional approaches increasingly challenging.

• Born during COVID-19, QuantHealth developed an AI-driven solution that effectively bridges the critical gap between preclinical and clinical stages. Their platform now processes thousands of trials annually, demonstrating remarkable precision in predicting outcomes.

• The platform combines biological knowledge graphs with deep learning models to create digital twins of both drugs and patients. This innovative approach spans more than 50 medical indications and multiple treatment modalities, enabling comprehensive trial simulation.

• Through partnerships with major pharmaceutical companies, QuantHealth has helped increase trial success rates by 15% while simultaneously reducing development timelines. Their simulation technology has made previously unfeasible trials possible.

Learn more about QuantHealth's innovative approach to clinical trial optimization at quanthealth.ai

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

From developing advanced technology for astronauts to revolutionizing medical device connectivity, every founders' innovation journey includes unexpected twists and turns. In this episode of the AWS Health Innovation Podcast, Yin He, Principal of Business Development for Healthcare & Life Sciences Startups at AWS, explores the transformative world of medical device cloud solutions with Alex Condon, COO and Co-founder of Galen Data. Their discussion reveals how Galen Data is helping medical device companies achieve FDA-compliant cloud connectivity in a fraction of the traditional time.

• Alex's experience in NASA contracting revealed striking parallels between spaceflight and medical device compliance requirements. This unique perspective helped shape Galen Data's approach to creating simplified, yet robust cloud infrastructure specifically for healthcare technology.

• Complex EHR integrations and stringent cybersecurity requirements create significant barriers to market entry. Galen Data addresses these challenges through standardized solutions and comprehensive expert support, enabling faster deployment while maintaining compliance.

• The platform's configurable nature allows it to serve both startups and enterprise-level organizations effectively. Each implementation is tailored to address specific organizational needs while maintaining regulatory compliance and operational efficiency.

• Detailed documentation practices and strategic relationship building proved crucial in the acquisition by Luxera Capital Partners. The company's organized approach to compliance and security documentation demonstrated significant value during the exit process.

• Their commitment to genuine community engagement and customer success has fostered lasting partnerships beyond traditional business relationships. This approach has established Galen Data as a trusted partner in medical technology innovation.

Learn more about Galen Data's innovative cloud platform for medical devices at galendata.com

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Guy Spigelman, EMEA Healthcare and Life Sciences Startups lead at AWS, sits down with Michel van Harten MD, CEO of myTomorrows, to explore how artificial intelligence is revolutionizing clinical trial recruitment. myTomorrows is transforming the patient-trial matching process, reducing hours of manual screening to mere minutes through sophisticated AI automation - all while maintaining exceptional accuracy standards.

• Driven by firsthand experiences with treatment access barriers, Michel van Harten MD, transitioned from clinical practice to leading myTomorrows, combining medical expertise with technological innovation to solve healthcare delivery challenges.

• The platform leverages advanced AI to create seamless connections between patients, physicians, and clinical trials, achieving an impressive 98% accuracy rate while reducing physician screening time by over 90%.

• Monthly patient speakers and mission-focused initiatives keep their 110-person team deeply connected to their purpose. This values-driven approach helps attract top talent while maintaining sustainable growth.

• Operating across 125 countries with 2,200+ physicians, the platform has facilitated treatment access for nearly 15,000 patients through expanded access programs and clinical trial matching.

• Through strategic pivots and technological advancement, myTomorrows has built a sustainable growth model, positioning themselves for growth equity funding and continued market expansion.

Learn more about myTomorrows at https://mytomorrows.com/

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Healthcare data fragmentation remains one of the most pressing challenges in modern medicine. In this episode, Mike Tarselli, Specialist Leader for HCLS Data & AI at AWS, explores innovative solutions with Mika Newton, CEO of xCures. Their platform is revolutionizing how healthcare organizations access and utilize patient data, transforming disconnected, and often complex medical records into actionable insights through advanced AI technology.

1. How did xCures evolve from cancer-specific solutions to a comprehensive healthcare platform?
   • Starting in oncology, xCures developed AI solutions to tackle complex cancer patient management. The platform's success in organizing and analyzing oncology records led to natural expansion across all medical conditions, demonstrating the universal need for better healthcare data management.
2. What makes xCures' approach to medical record management unique?
   • The platform leverages advanced AI and machine learning to convert fragmented medical records into structured, actionable data. This transformation enables healthcare providers to access comprehensive patient histories while maintaining strict HIPAA compliance standards.
3. How does the AWS partnership enable xCures' scalability?
   • By utilizing AWS infrastructure, xCures processes millions of medical records with enterprise-grade security. Their multi-tenant architecture supports rapid growth while maintaining the highest data protection standards required in healthcare.
4. What role does AI play in improving patient record management?
   • xCures employs sophisticated Bayesian models and natural language processing to convert complex medical documentation into searchable, meaningful data. Their semantic embedding technology provides crucial clinical context, enhancing healthcare decision-making.
5. What is xCures' vision for the future of healthcare data access?
   • The company aims to create internet-style healthcare interoperability, addressing critical staffing challenges while improving patient outcomes through enhanced data accessibility and integration.
6. How are healthcare organizations implementing xCures' technology?
   • Telehealth providers and diagnostic companies use the xCures platform to streamline patient care coordination, enabling comprehensive access to patient data during virtual consultations and diagnostic testing through their SaaS solution.

Learn more about xCures at https://xcures.com/

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

The convergence of artificial intelligence and biological engineering is ushering in a new era of drug design. On this episode of the AWS Health Innovation Podcast, Sanjit Misra speaks with Tharindi Hapuarachchi, VP of Platform Strategy & Operations at Generate:Biomedicines, about their groundbreaking work in generative biology. Through their innovative platform, they're revolutionizing how we design therapeutic proteins, bringing unprecedented speed and precision to drug development.

• Her journey from mathematics to bioengineering provides the perfect blend of analytical thinking and biological understanding needed for modern therapeutic development. This interdisciplinary expertise enables her to bridge the gap between computational design and practical applications in medicine.

• Their platform combines advanced machine learning with biological engineering in a novel "lab in the loop" system. This integration allows them to test millions of protein designs within weeks, dramatically accelerating the traditional drug discovery timeline.

• A 330-person team operates both computational models and wet labs under one roof, creating an integrated ecosystem where AI-designed proteins can be rapidly tested and validated for therapeutic use.

• Their COVID antibody development program showcases the platform's power, completing in just 17 months. The ability to simultaneously optimize multiple properties represents a significant advancement over traditional pharmaceutical development methods.

• Their system combines proprietary protein databases with 24/7 automated laboratories, enabling continuous learning and iteration in the protein design process. This infrastructure creates a powerful feedback loop that enhances the platform's capabilities over time.

• The platform aims to reduce development costs while accelerating therapeutic creation, potentially enabling more personalized treatments for underserved populations and improving access to breakthrough medicines.

Learn more about Generate:Biomedicines at generatebiomedicines.com

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

In a groundbreaking advancement for health monitoring, a device the size of a band-aid is transforming how we prevent medical emergencies. On this episode of the AWS Health Innovation Podcast, Yin He, Principal of Business Development for Healthcare & Life Sciences Startups, explores the future of patient care with Dr. Jim Mault, CEO and Founder of BioIntelliSense. Their conversation reveals how continuous vital sign monitoring is revolutionizing the century-old practice of patient observation.

1. How is BioIntelliSense transforming traditional vital sign monitoring?
• The BioButton device captures an unprecedented 1,440 measurements daily, enabling continuous, AI-powered health monitoring. This medical-grade wearable represents a paradigm shift from periodic to constant patient observation.
2. What makes the healthcare command center system unique?
• Healthcare providers can monitor up to 300 patients simultaneously through an innovative exception management system. The platform uses color-coding to transform complex data streams into actionable insights, similar to modern aviation control systems.
3. How does continuous monitoring impact patient recovery?
• The system has demonstrated an impressive 80% reduction in 30-day readmissions by bridging the critical monitoring gap between hospital discharge and home recovery, providing enhanced security for both patients and their families.
4. What role does cognitive computing play in healthcare data management?
• While healthcare facilities generate vast amounts of data, BioIntelliSense's cognitive computing approach processes this previously unused information into clear, actionable insights, following the successful evolution model of aviation safety systems.
5. How does BioIntelliSense ensure successful clinical adoption?
• The company employs a structured three-phase implementation process, focusing on education and transformation. Healthcare facilities using the BioButton system report significant improvements in patient outcomes and reductions in unplanned transfers.
6. What makes BioIntelliSense's approach sustainable?
• The company combines a subscription-based model with reusable devices to create both environmental and economic sustainability, while maintaining FDA compliance and clinical efficacy.

Learn more about BioIntelliSense at www.biointellisense.com

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.